SynbioTech Showcases TWK10® Research at Vitafoods Asia 2026 for GLP-1 Nutrition
SynbioTech, a leading biotechnology company, is set to present its Lactiplantibacillus plantarum TWK10® and microbiome CDMO platform at Vitafoods Asia 2026, scheduled for September 2-4 at the Queen Sirikit National Convention Center in Bangkok. This presentation comes at a time when GLP-1-based therapies are transforming the weight management landscape, prompting brands to focus on nutrition quality and muscle support rather than solely on appetite control. Sean Yang, Chief Operating Officer of SynbioTech, stated, "GLP-1 has broadened the weight management conversation beyond appetite control, emphasizing that eating less does not equate to better nourishment." The company aims to leverage its research on the gut-muscle axis, supported by 27 scientific publications, to highlight the potential of TWK10® in this emerging companion-nutrition category.
The shift in the weight management narrative is significant. Brands are now exploring products that not only assist in managing protein intake but also enhance muscle support and overall vitality. According to Morgan Stanley Research, the global GLP-1 drug market is projected to reach $190 billion by 2035, indicating a substantial growth opportunity for companion nutrition products that link weight management with protein utilization and gut health. This trend is particularly relevant for women's health brands, as consumers increasingly seek solutions that promote healthy aging and active lifestyles.
Research on TWK10® has demonstrated its efficacy in improving muscle function and mobility. In a 28-day human study, participants combining pea protein intake with resistance training showed increased blood concentrations of branched-chain amino acids (BCAAs) and essential amino acids (EAAs) when supplemented with TWK10®, compared to a control group. Additionally, an 18-week randomized clinical trial involving frail older adults revealed that high-dose TWK10® supplementation led to significant improvements in muscle strength and physical function, with a 51% enhancement in chair-stand performance and a 16.8% reduction in timed up-and-go test performance.
TWK10® is backed by extensive research, including nine human clinical studies and 27 scientific publications, establishing its relevance for brands targeting protein utilization, muscle support, and healthy aging. Furthermore, SynbioTech has achieved several regulatory milestones across Southeast Asia, facilitating faster market entry for brands utilizing TWK10®. The strain has received various health claims and recognitions, including a self-affirmed GRAS status in the U.S. and functional claim recognition in Korea.
At Vitafoods Asia 2026, SynbioTech will also showcase its integrated CDMO platform, which supports brands in developing market-ready products. This platform encompasses strain selection, formulation development, clinical study design, and regulatory documentation, enabling partners to efficiently navigate the complexities of product development in the rapidly evolving GLP-1 companion nutrition space. TWK10® has garnered international recognition, winning multiple awards for its applications in sports nutrition and healthy aging, further solidifying its position as a key ingredient in this emerging market.




